{"id":970353,"date":"2026-06-03T16:48:08","date_gmt":"2026-06-03T20:48:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-and-inceptive-form-strategic-ai-collaboration-to-accelerate-the-discovery-of-rnai-therapeutics\/"},"modified":"2026-06-03T16:48:08","modified_gmt":"2026-06-03T20:48:08","slug":"alnylam-and-inceptive-form-strategic-ai-collaboration-to-accelerate-the-discovery-of-rnai-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-and-inceptive-form-strategic-ai-collaboration-to-accelerate-the-discovery-of-rnai-therapeutics\/","title":{"rendered":"Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics"},"content":{"rendered":"

<\/p>\n

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics<\/b><\/p>\n

\u2212 Collaboration is valued at up to $2B with upfront consideration of $30M \u2212<\/i><\/p>\n

\u2212 Alliance pairs Alnylam\u2019s RNAi platform and 20+ years of proprietary data with Inceptive\u2019s foundation models and AI expertise to catalyze progress beyond rational drug design \u2013<\/i><\/p>\n

\u2212 Partnership designed to accelerate timelines and unlock innovative oligonucleotide designs \u2212<\/i><\/p>\n

CAMBRIDGE, Mass. & PALO ALTO, Calif.–(BUSINESS WIRE<\/a>)–Alnylam Pharmaceuticals, Inc.<\/a> (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc.<\/a>, which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cash and the purchase of Inceptive equity. Inceptive is eligible to receive additional payments based on the achievement of preclinical, regulatory, and commercial sales milestones.<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260603131911\/en\/<\/a><\/p>\n

\"Yvonne<\/p>\n

Yvonne Greenstreet<\/p>\n<\/div>\n

\nBy integrating Inceptive\u2019s generative AI models with Alnylam\u2019s R&D engine, Alnylam aims to accelerate the discovery of novel RNAi therapeutics as it advances ambitious pipeline expansion goals as part of its Alnylam 2030<\/i> strategy.<\/p>\n

\n\u201cWe\u2019re thrilled to partner with Inceptive to push the boundaries of what is possible in the discovery of RNAi medicines,\u201d said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. \u201cInceptive stands apart as one of the most visionary companies working at the intersection of AI and biology. It is led by pioneers of the AI revolution and driven by an ambitious mission to fundamentally reinvent how RNA medicines are designed. Together, we have an extraordinary opportunity to accelerate the creation of transformative medicines with a speed, ingenuity, and sophistication that simply has not been possible before.\u201d<\/p>\n

\nInceptive\u2019s foundation model learns the patterns underlying biology and hence can adapt to diverse therapeutic modalities without retraining. In joint exploratory work, the model achieved exceptional performance within weeks, uncovering meaningful biological insights from relatively small datasets to characterize siRNA molecules, the active ingredient in RNAi therapeutics.<\/p>\n

\n“Most drug design still works through a process of trial and error, testing thousands of molecules and hoping something sticks,\u201d said Jakob Uszkoreit, Inceptive co-founder and CEO. \u201cInceptive was built on a different premise: that life follows rules of such complexity that only AI can learn them. Alnylam\u2019s breakthrough platform and scientific vision are an ideal match for AI. Together, we\u2019re not just accelerating drug discovery; we\u2019re changing the way we understand and improve life.\u201d<\/p>\n

Generalizable Platforms Open New Therapeutic Design Spaces<\/b><\/p>\n

\nThe collaboration pairs Alnylam\u2019s RNAi leadership with Inceptive\u2019s foundation models and AI expertise to catalyze and accelerate progress in nucleic-acid based drug design. Inceptive focuses on developing models for sequence-based medicines such as RNAi therapeutics, which were pioneered by Alnylam.<\/p>\n